At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 753 enrolled
Drug / intervention
rLP2086 +3 morebiological
Likely dose
rLP2086 0.5 mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Randomized, Placebo-controlled, Single-blind Trial To Assess The Safety, Tolerability, And Immunogenicity Of Repevax(Registered) And Bivalent Rlp2086 Vaccine When Administered Concomitantly In Healthy Subjects Aged Greater Than Or Equal To 11 To <19 Years
In Brief
A Phase 2 clinical trial evaluating rLP2086, Repevax, and 1 other intervention for Meningococcal Vaccine and 4 related conditions. Completed, enrolled 753 participants across 36 sites in 3 countries.
Detailed Summary
This study is to look at a new vaccine that might prevent meningococcal disease, and to look at the safety of the new vaccine as well as how it is tolerated when given together with Repevax. The study will be done in healthy adolescents.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMeningococcal Vaccine, rLP2086, Repevax, N Meningitidis Serogroup B, Meningitis
CountriesFinland, Germany, Poland
Collaborators--
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartMar 2011
First PostedMar 2011
Primary CompletionOct 2012
Study CompletionFeb 2013
TodayJul 2026
First PostedMar 25, 2011
Enrollment StartMar 18, 2011
Primary CompletionOct 8, 2012
Study CompletionFeb 19, 2013
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 15.3 years ago
Interventions
rLP2086biological
0.5 mL dose, given at 0, 2 and 6 months.
Repevaxbiological
0.5 mL dose, given at 0 months.
Salinebiological
0.5 mL dose, given at 0, 2 and 6 months.
Repevaxbiological
0.5 mL dose, given at 0 months.